Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile.

Valentina GrajalesRoberto ContieriWei Shen TanMarta FloresMarcela SchultzRodrigo PinochetAlberto BustamanteAshish M KamatMario I Fernández

Published in: Bladder cancer (Amsterdam, Netherlands) (2023)

1331 BCG treatment was associated with worse recurrence free rate and HG-recurrence rate in our cohort. Patients with RD had lower discontinuation treatment rates due to a reduced toxicity profile. These findings would suggest that RD BCG would compromise oncological outcomes in HR-NMIBC patients.

Keyphrases

muscle invasive bladder cancer
type diabetes
oxidative stress
newly diagnosed
ejection fraction
skeletal muscle
metabolic syndrome
weight loss
single molecule